Ivantis Inc. expanded its presence in the novel drugs and devices to lower intraocular pressure market with the launch of Hydrus microstent: a device used in minimally invasive glaucoma surgery

Increasing approval of drugs and devices associated with the treatment of glaucoma from regulatory bodies is projected to foster the growth of the novel drugs and devices to lower intraocular pressure market. For instance, in May 2019, Ivantis Inc. received an approval from the U.S. Food and Drug Administration (FDA) for Hydrus microstent. It is a device used in minimally invasive glaucoma surgery. It is developed to lower eye pressure in patients with open-angle glaucoma.

North America is expected to lead the global novel drugs and devices to lower intraocular pressure market over the forecast period due to increasing FDA approval for drug launch. For instance, in September 2018, Sun Pharmaceuticals Industries Ltd. received approval from U.S. FDA for Xelpros (latanoprost ophthalmic emulsion) for the treatment of glaucoma. It reduces the elevated intraocular pressure in the eye and has been designed with the help of Swollen Micelle Microemulsion technology.

Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2670

In March 2020, Allergan plc a global pharmaceutical company with more than 70 years of heritage in eye care announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for DURYSTA™ (bimatoprost implant) 10 mcg for intracameral administration

In October 2017, Nicox S.A. the international ophthalmic company, and pSivida Corp, a developer of sustained-release drug products and technologies announced their entry into a collaboration agreement to explore the potential of combining Nicox's nitric oxide (NO)-donating compounds with pSivida's bioerodible sustained release drug delivery system, to develop a sustained release drug to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension

Intraocular Pressure, also known as the IOP, is usually measured by a specialized medical device known as the Intraocular Pressure (IOP) monitor. This medical device is placed on the eye itself and measures eye pressure from multiple angles. In order for one to have high levels of IOP, one must regularly measure their IOP by the use of an Intraocular Pressure Monitor, which measures a patient's IOP and thus the pressure of lens or eyeballs. The lens, however, should never be placed inside of the patient's eye, unless the monitor is specifically designed to do just that. This disease causes severe vision loss and is usually caused by the buildup of internal pressure inside the eye. Once this pressure rises, it causes damage to the optic nerve and leads to loss of vision. New drugs from this company called Lumigan showed promising results in animal models of angle-closure glaucoma.

"Flat USD 2000 OFF"

Buy This Research Study Report @ https://www.coherentmarketinsights.com/promo/buynow/2670

Major Key Players Are: Mati Therapeutics Inc, BioLight Lifesciences Ltd., IOPtima Ltd., Eye Sonix, Bausch & Lomb Inc., Sun Pharmaceutical Industries Ltd., Allergan, Alcon Inc., Glaukos Corporation, and Pfizer Inc.

Table of Content

Global Novel Drugs and Devices to Lower Intraocular Pressure Market Research Report

Section 1: Global Novel Drugs and Devices to Lower Intraocular Pressure Industry Overview
Section 2: Global Economic Impact on Novel Drugs and Devices to Lower Intraocular Pressure Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Novel Drugs and Devices to Lower Intraocular Pressure Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Novel Drugs and Devices to Lower Intraocular Pressure Market Forecast

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

More Reports:

3D Cell Culture Market - https://www.globenewswire.com/en/news-release/2021/06/08/2243756/0/en/Global-3D-Cell-Culture-Market-to-Surpass-US-11-335-1-Million-by-2027-Says-Coherent-Market-Insights-CMI.html

Human Microbiome Market - https://www.globenewswire.com/en/news-release/2021/06/03/2241395/0/en/Global-Human-Microbiome-Market-to-Surpass-US-306-351-2-Million-by-2028-Says-Coherent-Market-Insights-CMI.html

This release was published on openPR.